Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received an average rating of “Hold” from the nine analysts that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $8.24.

A number of research analysts have recently commented on the company. HC Wainwright lowered their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Guggenheim lowered their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Wedbush restated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Wells Fargo & Company reduced their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Finally, UBS Group reduced their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL opened at $2.43 on Wednesday. Zentalis Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $18.07. The stock has a 50 day simple moving average of $2.65 and a two-hundred day simple moving average of $3.11. The stock has a market cap of $173.17 million, a P/E ratio of -0.98 and a beta of 1.81.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka bought 60,000 shares of Zentalis Pharmaceuticals stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingmar Bruns bought 20,000 shares of Zentalis Pharmaceuticals stock in a transaction on Thursday, February 6th. The stock was acquired at an average cost of $2.28 per share, with a total value of $45,600.00. Following the acquisition, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its stake in shares of Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 14.1% in the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock worth $173,000 after buying an additional 7,058 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Zentalis Pharmaceuticals by 26.8% in the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock worth $105,000 after buying an additional 7,305 shares during the last quarter. Carson Advisory Inc. boosted its stake in shares of Zentalis Pharmaceuticals by 55.8% in the 3rd quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after buying an additional 8,800 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth $37,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.